3.33
4.86%
-0.17
After Hours:
3.33
Lixte Biotechnology Holdings Inc stock is currently priced at $3.33, with a 24-hour trading volume of 12,501.
It has seen a -4.86% decreased in the last 24 hours and a +44.16% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $3.46 pivot point. If it approaches the $3.28 support level, significant changes may occur.
Lixte Biotechnology Holdings Inc Stock (LIXT) Financials Data
Lixte Biotechnology Holdings Inc (LIXT) Net Income 2024
LIXT net income (TTM) was -$5.09 million for the quarter ending December 31, 2023, a +19.41% increase year-over-year.
Lixte Biotechnology Holdings Inc (LIXT) Cash Flow 2024
LIXT recorded a free cash flow (TTM) of -$4.29 million for the quarter ending December 31, 2023, a +6.90% increase year-over-year.
Lixte Biotechnology Holdings Inc (LIXT) Earnings per Share 2024
LIXT earnings per share (TTM) was -$2.70 for the quarter ending December 31, 2023, a +32.84% growth year-over-year.
Lixte Biotechnology Holdings Inc Stock (LIXT) Latest News
Gold Moves Higher; Velo3D Shares Plummet
Benzinga
Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Crude Oil Edges Lower; PaySign Shares Spike Higher
Benzinga
Dow Jumps Over 200 Points; UniFirst Posts Downbeat Earnings
Benzinga
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
GlobeNewswire Inc.
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI
GlobeNewswire Inc.
About Lixte Biotechnology Holdings Inc
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.
Cap:
|
Volume (24h):